This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Insiders Love Right Now

Gilead Sciences

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Insiders are buying up a decent amount of stock in Gilead Sciences (GILD), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. Insiders are loading up into strength here since this stock is u over 23% so far in 2012.

Gilead Sciences has a market cap of $33.7 billion and an enterprise value of $31.9 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 12.61 and a forward price-to-earnings of 10.27. Its estimated growth rate for this year is -1%, and for next year it's pegged at 14.1%. This is a cash-rich company, since the total cash position on its balance sheet is $9.96 billion and its total debt is $7.92 billion.

A director just bought 10,000 shares, or about $439,000 worth of stock, at $44 per share.

From a technical perspective, GILD is currently trading above its 200-day moving average and right below its 50-day moving average, which is neutral trendwise. This stock recently gapped down from over $54 to below $45 a share on monster volume. That huge gap down has done some technical damage on the chart that could take some time to fix.

If you're bullish on GILD, I would look for long-biased trades once this stock moves back above its 50-day moving average of $44.90 on high-volume. Look for volume on a move and close back above that level that's near of well above its three-month average action of 10,773,400 shares.

If we get that action soon, I would then add to any long positions once GILD trades above its gap down day high of $48 with volume. Look for some of that gap to get filled if $48 is taken out with volume. I would completely avoid any long biased traders in GILD if its recent low of $43.81 a share is taken out on high-volume.

Gilead shows up on a list of Health Care Stocks Bought and Sold by Hedge Funds in the most recent quarter.

5 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs